IGM Biosciences and ADC Therapeutics to Evaluate Imvotamab (IGM-2323) + ZYNLONTA in R/R B-cell NHL Patients November 16, 2022
First Patient Treated in Ph 1/2 Clinical Trial of MB-106 in B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia October 12, 2022
